BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 24251360)

  • 1. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
    Verhoef TI; Ragia G; de Boer A; Barallon R; Kolovou G; Kolovou V; Konstantinides S; Le Cessie S; Maltezos E; van der Meer FJ; Redekop WK; Remkes M; Rosendaal FR; van Schie RM; Tavridou A; Tziakas D; Wadelius M; Manolopoulos VG; Maitland-van der Zee AH;
    N Engl J Med; 2013 Dec; 369(24):2304-12. PubMed ID: 24251360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
    Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
    J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
    Stergiopoulos K; Brown DL
    JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon.
    Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Manolopoulos VG; Maitland-van der Zee AH;
    J Thromb Haemost; 2017 Mar; 15(3):454-464. PubMed ID: 27992949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials.
    Tang T; Liu J; Zuo K; Cheng J; Chen L; Lu C; Han S; Xu J; Jia Z; Ye M; Pei E; Zhang X; Li M
    J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):387-94. PubMed ID: 25575537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
    van Schie RM; Wessels JA; le Cessie S; de Boer A; Schalekamp T; van der Meer FJ; Verhoef TI; van Meegen E; Rosendaal FR; Maitland-van der Zee AH;
    Eur Heart J; 2011 Aug; 32(15):1909-17. PubMed ID: 21636598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study.
    van Schie RM; el Khedr N; Verhoef TI; Teichert M; Stricker BH; Hofman A; Buhre PN; Wessels JA; Schalekamp T; le Cessie S; van der Meer FJ; Rosendaal FR; de Boer A; Maitland-van der Zee AH; Visser LE
    Pharmacogenomics; 2012 Aug; 13(11):1239-45. PubMed ID: 22920394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of genotype-guided dosing of warfarin.
    Pirmohamed M; Burnside G; Eriksson N; Jorgensen AL; Toh CH; Nicholson T; Kesteven P; Christersson C; Wahlström B; Stafberg C; Zhang JE; Leathart JB; Kohnke H; Maitland-van der Zee AH; Williamson PR; Daly AK; Avery P; Kamali F; Wadelius M;
    N Engl J Med; 2013 Dec; 369(24):2294-303. PubMed ID: 24251363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do pharmacogenetics have a role in the dosing of vitamin K antagonists?
    Furie B
    N Engl J Med; 2013 Dec; 369(24):2345-6. PubMed ID: 24251364
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenetics and coumarin dosing--recalibrating expectations.
    Zineh I; Pacanowski M; Woodcock J
    N Engl J Med; 2013 Dec; 369(24):2273-5. PubMed ID: 24328463
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
    Wolkanin-Bartnik J; Pogorzelska H; Szperl M; Bartnik A; Koziarek J; Bilinska ZT
    Pharmacogenet Genomics; 2013 Nov; 23(11):611-8. PubMed ID: 24108193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
    van Schie RM; Wadelius MI; Kamali F; Daly AK; Manolopoulos VG; de Boer A; Barallon R; Verhoef TI; Kirchheiner J; Haschke-Becher E; Briz M; Rosendaal FR; Redekop WK; Pirmohamed M; Maitland van der Zee AH
    Pharmacogenomics; 2009 Oct; 10(10):1687-95. PubMed ID: 19842940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
    Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Maitland-van der Zee AH; ;
    Thromb Res; 2015 Jul; 136(1):94-100. PubMed ID: 25971661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
    Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
    Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.
    Verhoef TI; Redekop WK; Daly AK; van Schie RM; de Boer A; Maitland-van der Zee AH
    Br J Clin Pharmacol; 2014 Apr; 77(4):626-41. PubMed ID: 23919835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacogenetic versus a clinical algorithm for warfarin dosing.
    Kimmel SE; French B; Kasner SE; Johnson JA; Anderson JL; Gage BF; Rosenberg YD; Eby CS; Madigan RA; McBane RB; Abdel-Rahman SZ; Stevens SM; Yale S; Mohler ER; Fang MC; Shah V; Horenstein RB; Limdi NA; Muldowney JA; Gujral J; Delafontaine P; Desnick RJ; Ortel TL; Billett HH; Pendleton RC; Geller NL; Halperin JL; Goldhaber SZ; Caldwell MD; Califf RM; Ellenberg JH;
    N Engl J Med; 2013 Dec; 369(24):2283-93. PubMed ID: 24251361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients benefit from genetics-guided coumarin anticoagulant therapy.
    Maitland-van der Zee AH; Daly AK; Kamali F; Manolopoulous VG; Verhoef TI; Wadelius M; de Boer A; Pirmohamed M;
    Clin Pharmacol Ther; 2014 Jul; 96(1):15-7. PubMed ID: 24942396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype-guided dosing of vitamin K antagonists.
    Cavallari LH; Kittles RA; Perera MA
    N Engl J Med; 2014 May; 370(18):1763. PubMed ID: 24785218
    [No Abstract]   [Full Text] [Related]  

  • 20. Genotype-guided dosing of vitamin K antagonists.
    Koller EA; Roche JC; Rollins JA
    N Engl J Med; 2014 May; 370(18):1761. PubMed ID: 24785214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.